Session (CTI)

It is increasingly recognized that systematic, current, and reliable real-world data (RWD)-based insights about the characteristics, care, and outcomes of the indicated population are critical for optimized clinical development and commercial strategy. However, sources of RWD are often limited in aspects such as length of follow-up time, representativeness, completeness of lab and radiologic findings, and capture of scale assessments. These limitations can be addressed by technological solutions, such as tokenization and natural language processing, which facilitate the assembly of broader, richer, and more complete data generated during routine clinical care. Extending the application of tokenization to uses such as linking RWD with data from compassionate-use programs and clinical trials further extracts value from existing data infrastructure. For example, clinical trial data linked with RWD provides additional insights to address questions about how to design, operate and facilitate interpretability of Phase II and III clinical trials. In this presentation, Dr. Nicolle Gatto, Chief Science Officer of Aetion, a Datavant Company, will discuss how such technology solutions are essential to ensuring impactful RWE generation and a comprehensive evidence base for informed decision-making. Industry use cases will be discussed for illustration.

Sponsored by Corporate Partner, Datavant